Newsoara Biopharma Co., Ltd.
Clinical trials sponsored by Newsoara Biopharma Co., Ltd., explained in plain language.
-
New oral pill HPP737 takes on psoriasis in Head-to-Head trial
Disease control CompletedThis Phase 3 trial tests whether an experimental oral drug, HPP737, can reduce psoriasis severity in adults with moderate-to-severe plaque psoriasis. Participants take HPP737 or an active control drug daily for 16 weeks. Researchers measure skin clearance using standard scores li…
Phase: PHASE3 • Sponsor: Newsoara Biopharma Co., Ltd. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New oral pill HPP737 aims to clear psoriasis in phase 3 trial
Disease control CompletedThis Phase 3 trial tests whether an oral drug called HPP737 can safely improve moderate-to-severe plaque psoriasis in adults. Participants take HPP737 or a placebo daily for 16 weeks, with doctors measuring skin clearance using standard scores like PASI. The study aims to see if …
Phase: PHASE3 • Sponsor: Newsoara Biopharma Co., Ltd. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New oral pill HPP737 aims to clear psoriasis in phase II trial
Disease control CompletedThis trial tests whether an oral drug called HPP737 can safely improve moderate-to-severe plaque psoriasis in adults. Participants take either HPP737 or a placebo daily for 85 days. Researchers measure skin improvement using standard scoring tools and track any side effects. The …
Phase: PHASE2 • Sponsor: Newsoara Biopharma Co., Ltd. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC